Chronic kidney disease (CKD) is a common clinical disease which slowly occurs on the basis of various chronic kidney diseases. About 10% ~ 16% of adults suffer from different degrees of CKD, and its incidence is increasing year by year, which has gradually become a global health problem.
From the clinical point of view, CKD is a disease with gradually deteriorating renal function caused by many factors, and it is difficult to treat it. At present, the main treatment methods are to actively treat the primary disease, control related risk factors and delay the progress of the disease.
The biological effect of molecular hydrogen has quickly become a research hotspot in recent years. Studies have proved that molecular hydrogen has antioxidant, anti-inflammatory and anti-apoptotic effects in many diseases, including kidney diseases.
Studies have shown that creatinine clearance rate increased in acute renal injury (CIAKI) rats treated with hydrogen. Histological analysis of kidney showed that hydrogen inhalation could improve the formation of protein cast and renal tubular necrosis. The analysis showed that hydrogen inhalation could significantly reduce the apoptosis of kidney cells, the expression of Caspase 3 and the expression of 8- hydroxydeoxyguanosine, a marker of oxidative stress. The results showed that hydrogen inhalation could alleviate renal cell apoptosis and oxidative stress, and improve the severity of CIAKI.
Therefore, based on the safety and effectiveness of hydrogen in basic and clinical research, the clinical trial of treating CKD with hydrogen is worth looking forward to.
【 Clinical trial 】 Hydrogen improves renal function in patients with chronic kidney disease
This is a randomized, parallel, controlled clinical trial. The hospitalized patients in the Navy General Hospital from January 2018 to December 2019 were diagnosed as CKD stage 3-4. A comparative study of 100 patients was conducted to evaluate the effect of hydrogen inhalation on renal function and quality of life of CKD patients.
Patients were randomly divided into an experimental group and a control group. Patients in the experimental group inhaled hydrogen plus basic treatment according to the plan, and the inhalation flow rate was 300ml/min (NB-X71A of Shanghai Nanometer Technology Co., Ltd.) for 6h/ day for 7 days. Patients in the control group were only given corresponding basic treatment. The basic information and clinical data of patients were collected, and the changes of renal function, scores of quality of life related scales and laboratory indexes of the experimental group and the control group were analyzed.
The final result showed that compared with the control group, the renal function indexes (Scr, eGFR, BUN, CysC) and the scores of quality of life scale (PSQI, VAS) in the experimental group were improved in different degrees after hydrogen inhalation treatment.
Analysis of the final results verified the role of hydrogen in protecting renal function and improving quality of life of CKD patients.
Exploring the related mechanism of its action, it is found that hydrogen inhalation can increase the activity of SOD and GSH-PX in serum and urine of CKD patients, reduce the level of 8-0HDG in serum and urine, and reduce the expression of TNF-aIL6 in serum, thus improving the oxidative stress and microinflammation of CKD. It provides an effective explanation for the mechanism of the kidney function and sleep quality of CKD patients in the above clinical research: hydrogen inhalation may play a role in protecting kidney function and improving quality of life by improving oxidative stress and microinflammation of CKD patients.